SOCIAL media influencers and other advertisers are being warned not to promote diabetes treatment, Ozempic (semagludtide) for weight-loss, by the Therapeutic Goods Administration (TGA).
In a statement released yesterday, the TGA said advertising of the prescription-only medication was "prohibited".
"Advertising to the public is a contravention of the [Therapeutic Goods] Act [1989] that can result in jail time and criminal penalties of up to $888,000 for individuals [or] $4.44 million for corporations, [and] civil penalties of up to $1.11 million for individuals or $11.1 million for corporations," the TGA said.
Nova Nordisk has previously warned that the medication was likely to be unavailable in Australia until late Mar 2023.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Dec 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Dec 22
